Sam Brusco, Associate Editor03.08.22
SeaSpine has promoted two of its executives. Dr. Frank Vizesi, who joined the company in 2015 as director of R&D for orthobiologics has been elevated to chief scientific officer. Shaeffer Bannigan, who joined the company in 2018 as director of product development for spinal implants, was promoted to VP of product development for spinal implant. Bannigan joins SeaSpine’s senior leadership team as a result.
Under Dr. Vizesi’s leadership the team deepened scientific research to differentiate SeaSpine’s demineralized bone matrix (DBM) products.
“Today, SeaSpine holds the #2 position in the U.S. DBM market and Frank has been instrumental in this success through his impact on our products with scientific support,” SeaSpine president and CEO Keith Valentine told the press. “In his new role as chief scientific officer, Frank will continue to lead the Orthobiologics development and clinical teams, while also working directly with me and the leaders of our Spinal Implant and Enabling Technology groups to drive pre-clinical and clinical research across all SeaSpine product lines.”
Under his tenure, Bannigan and his team executed over 45 limited or full product launches. Today over 75 percent of the company’s spinal implants revenue in generated from products rolled out in the last five years.
“Under Shaeffer’s leadership, the Spinal Implants product development team has closed the many gaps that existed in the SeaSpine product portfolio when he joined,” said Valentine. “Shaffer has been key in advancing our implant and fixation portfolios in critical areas. The innovation expectations on Shaeffer and his team will continue as we merge our Enabling Technology and Orthobiologics franchises to build our next generation of market-taking solutions.”
Under Dr. Vizesi’s leadership the team deepened scientific research to differentiate SeaSpine’s demineralized bone matrix (DBM) products.
“Today, SeaSpine holds the #2 position in the U.S. DBM market and Frank has been instrumental in this success through his impact on our products with scientific support,” SeaSpine president and CEO Keith Valentine told the press. “In his new role as chief scientific officer, Frank will continue to lead the Orthobiologics development and clinical teams, while also working directly with me and the leaders of our Spinal Implant and Enabling Technology groups to drive pre-clinical and clinical research across all SeaSpine product lines.”
Under his tenure, Bannigan and his team executed over 45 limited or full product launches. Today over 75 percent of the company’s spinal implants revenue in generated from products rolled out in the last five years.
“Under Shaeffer’s leadership, the Spinal Implants product development team has closed the many gaps that existed in the SeaSpine product portfolio when he joined,” said Valentine. “Shaffer has been key in advancing our implant and fixation portfolios in critical areas. The innovation expectations on Shaeffer and his team will continue as we merge our Enabling Technology and Orthobiologics franchises to build our next generation of market-taking solutions.”